| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6000432 | Thrombosis Research | 2016 | 4 Pages |
Abstract
â¢Low molecular weight heparin (LMWH) is the treatment of choice in cancer related VTE.â¢Managing cancer related recurrent VTE on therapeutic anticoagulation is a challenge.â¢Current guidelines recommend dose escalation of LMWH with ant-Xa monitoring.â¢Combined factor Xa $_amp_$amp; factor IIa inhibitors may be an option in refractory thrombosis.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Deepa R.J. Arachchillage, Martin Besser, Rhona Maclean, Trevor Baglin, Joost J. van Veen,